Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status. Treatment for multiple myeloma includes initial treatment (induction) which is the first treatment a patient receives for cancer followed by ongoing treatment (maintenance) which is given after initial treatment to help keep the cancer from coming back. There are three combinations of four different drugs being studied. Bortezomib is one of the drugs that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide works by helping bone marrow to produce normal blood cells and killing cancer cells. Anti-inflammatory drugs, such as dexamethasone, lower the body’s immune response and are used with other drugs in the treatment of some types of cancer. Daratumumab and hyaluronidase-fihj is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Patients receive 1 of 3 combinations of these drugs for treatment to determine which combination of study drugs works better to shrink and control multiple myeloma.
Inclusion Criteria
- Participants must have documented multiple myeloma satisfying standard International Myeloma Working Group (IMWG) diagnostic criteria within 28 days prior to registration for participants with no prior therapy, or within 28 days prior to initiation of first induction course for participants who had prior therapy. Participants meeting IMWG criteria for multiple myeloma with amyloid deposits are eligible
- Participants must have measurable disease within 28 days prior to registration (or prior to initiation of first induction course for participants who had prior therapy) as defined by any of the following: * Immunoglobulin (Ig) G myeloma (serum monoclonal paraprotein [M-protein] level >= 0.5 gram/deciliter [g/dL] or urine M-protein level >= 200 milligram[mg]/24 hours[hrs]); OR * IgA, IgM, IgD, or IgE multiple myeloma (serum M-protein level >= 0.2 g/dL or urine M-protein level >= 200 mg/24 hrs); OR * Light chain multiple myeloma (serum immunoglobulin free light chain >= 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio)
- Participants must not have plasma cell leukemia per IMWG diagnostic criteria
- Note: All disease must be assessed and documented on the baseline/pre-registration and tumor assessment form
- Localized palliative radiation therapy for multiple myeloma is allowed
- An emergency use of a short course of corticosteroid (equivalent of dexamethasone 160 mg) any time before registration
- Participants must not have received any prior systemic therapy for multiple myeloma with the exception of up to one complete cycle of a non-anti-CD38 based myeloma regimen (1 cycle = 21 or 28 days) depending on the regimen being used
- Participants must have a calculated myeloma frailty index (Myeloma Frailty Score Calculator; https://stattools.crab.org/R/Myeloma_Frailty_Index.html or http://www.myelomafrailtyscorecalculator.net/) categorized as frail or intermediate fit (regardless of age) within 28 days prior to registration * This is the same calculator available on both sites
- For participants meeting “frail” status: * Participants with any degree of kidney dysfunction are allowed
- For participants meeting “frail” status: * Hemoglobin >= 7 g/dL (must be performed within 28 days prior to registration) ** Note: growth factor and transfusion utilization are allowed if cytopenias are considered secondary to bone marrow involvement from MM)
- For participants meeting “frail” status: * Platelets >= 50 x 10^9/L (must be performed within 28 days prior to registration) ** Note: growth factor and transfusion utilization are allowed if cytopenias are considered secondary to bone marrow involvement from MM)
- For participants meeting “frail” status: * Absolute neutrophil count (ANC) >= 0.75 x 10^9/L (must be performed within 28 days prior to registration) ** Note: growth factor and transfusion utilization are allowed if cytopenias are considered secondary to bone marrow involvement from MM)
- For participants meeting “intermediate fit” status, at least one of the following five criteria must be present (NOTE: As long as participants meet any of the below criteria for intermediate fit, the remaining criteria are not mandatory): * Kidney dysfunction showing calculated creatinine clearance (CrCl) < 30 ml/min * Hemoglobin >= 7 and < 8 g/dL * Platelets >= 50 and < 75 x 10^9/L * ANC >= 0.75 and < 1 x 10^9/L ** Note: growth factor and transfusion utilization are allowed as long as cytopenias are considered secondary to bone marrow involvement from MM) * Revised International Staging System (R-ISS) stage III disease
- Participants must have a complete medical history and physical exam within 28 days prior to registration
- Participants must have whole body imaging within 60 days prior to registration. The recommended method of imaging is a PET/CT; a low-dose whole body CT scan or whole-body magnetic resonance imaging (MRI) or skeletal survey should be done only if a PET/CT scan cannot be done or is non-feasible. A PET/CT scan from skull base to mid-thigh is acceptable. This must be documented in the comments section of the Onstudy form. Scan must be completed prior to initiation of any treatment for multiple myeloma with the exception of localized palliative radiation therapy
- Total bilirubin =< 2 times institutional upper limit of normal (ULN) unless history of Gilbert’s disease. Participants with history of Gilbert’s disease must have total bilirubin =< 5 x institutional ULN (within 28 days prior to registration)
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 × institutional ULN (within 28 days prior to registration)
- Participants must have adequate cardiac function, as assessed by the treating physician within 14 days prior to registration. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification and must not be assessed as class 3 or 4
- Participants with known diabetes must show evidence of controlled disease within 14 days prior to registration. Uncontrolled diabetes is defined as: A glycosylated hemoglobin (Hg)A1C > 9%
- Participants must have an Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status score of 0-2 (Note: Participants with ECOG/Zubrod performance score [PS] 3, especially where the deterioration of PS is considered secondary to the MM diagnosis, will be allowed)
- Participants with known human immunodeficiency virus (HIV)-infection must be receiving anti-retroviral therapy and have an undetectable viral load test on the most recent test result obtained, within 6 months prior to registration
- All participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on suppressive therapy within 28 days prior to registration. Participants with known history of HBV must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. * EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-hepatitis B surface antigen [HBs] positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.
- Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, participant must have an undetectable HCV viral load within 28 days prior to registration
- Participants must not have evidence of greater than or equal to grade 3 peripheral neuropathy prior to study registration
- Participants must not have uncontrolled blood pressure within 14 days prior to registration, to be determined by treating physician
- Participants must not have known allergies to any of the study drugs
- Participants must not have had a major surgery within 14 days prior to registration and be fully recovered from any prior surgery prior to registration
- Participants must not have a known or uncontrolled chronic obstructive pulmonary disease with prior testing resulting in a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal
- Participants must not have received vaccination with live attenuated vaccines within 28 days prior to registration
- Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen
- Participants of childbearing potential must have a negative pregnancy test 14 days prior to registration and again within 24 hours prior to starting treatment on cycle 1, day 1. Participants must not be pregnant or nursing. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 24 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
- Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) specimen tracking system
- Participants who are able to complete the patient-reported outcomes measures in English or Spanish must be offered the opportunity to participate in the PRO portion of the study
- Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
Additional locations may be listed on ClinicalTrials.gov for NCT05561387.
Locations matching your search criteria
United States
Alaska
Anchorage
Arizona
Phoenix
Arkansas
Fayetteville
Ft. Smith
Little Rock
Rogers
Springdale
California
Antioch
Arroyo Grande
Burbank
Cameron Park
Carmichael
Duarte
Dublin
Elk Grove
Fremont
Fresno
Huntington Beach
Irvine
Lancaster
Long Beach
Marysville
Merced
Modesto
Napa
Newport Beach
Oakland
Palo Alto
Rancho Cordova
Rancho Mirage
Redwood City
Richmond
Rocklin
Rohnert Park
Roseville
Sacramento
San Francisco
San Jose
San Leandro
San Luis Obispo
San Rafael
Santa Clara
Santa Maria
Santa Rosa
South Pasadena
South San Francisco
Stockton
Torrance
Truckee
Upland
Vacaville
Vallejo
Walnut Creek
Woodland
Colorado
Colorado Springs
Denver
Durango
Golden
Grand Junction
Lafayette
Lakewood
Littleton
Lone Tree
Longmont
Parker
Pueblo
Thornton
Westminster
Wheat Ridge
Connecticut
Derby
Fairfield
Glastonbury
Greenwich
Guilford
Hartford
New Haven
North Haven
Stamford
Torrington
Trumbull
Waterbury
Waterford
West Haven
Florida
Fort Lauderdale
Gainesville
Jacksonville
Jupiter
Hawaii
Honolulu
Idaho
Boise
Caldwell
Coeur D'Alene
Emmett
Fruitland
Meridian
Nampa
Post Falls
Sandpoint
Twin Falls
Illinois
Alton
Aurora
Bloomington
Burr Ridge
Canton
Carbondale
Carterville
Carthage
Centralia
Danville
Decatur
Dixon
Effingham
Eureka
Galesburg
Hines
Homer Glen
Kewanee
Macomb
Mattoon
Maywood
Melrose Park
Mount Vernon
Normal
O'Fallon
Ottawa
Pekin
Peoria
Peru
Princeton
Springfield
Urbana
Washington
Yorkville
Indiana
Crown Point
Dyer
Hobart
Indianapolis
Munster
Valparaiso
Iowa
Ankeny
Bettendorf
Carroll
Cedar Rapids
Clive
Council Bluffs
Creston
Des Moines
Fort Dodge
Iowa City
Waukee
West Des Moines
Kansas
Garden City
Great Bend
Leavenworth
Pittsburg
Topeka
Kentucky
Bardstown
Corbin
Lexington
London
Mount Sterling
Maryland
Baltimore
Michigan
Alma
Alpena
Ann Arbor
Battle Creek
Brighton
Canton
Caro
Chelsea
Clarkston
Dearborn
Detroit
East China
Escanaba
Farmington Hills
Flint
Gladwin
Grand Rapids
Grosse Pointe Woods
Kalamazoo
Lansing
Livonia
Macomb Township
Marlette
Midland
Mount Pleasant
Muskegon
Niles
Norton Shores
Pontiac
Reed City
Royal Oak
Saginaw
Saint Joseph
Sterling Heights
Tawas City
Traverse City
Troy
Warren
West Branch
Wyoming
Ypsilanti
Minnesota
Aitkin
Baxter
Bemidji
Brainerd
Burnsville
Cambridge
Coon Rapids
Crosslake
Deer River
Detroit Lakes
Duluth
Edina
Ely
Fosston
Hibbing
International Falls
Maple Grove
Maplewood
Minneapolis
Monticello
Moose Lake
New Ulm
Park Rapids
Pequot Lakes
Pine River
Princeton
Robbinsdale
Rochester
Saint Louis Park
Saint Paul
Sandstone
Shakopee
Staples
Stillwater
Thief River Falls
Virginia
Waconia
Willmar
Woodbury
Worthington
Wyoming
Missouri
Ballwin
Bolivar
Branson
Cape Girardeau
Farmington
Jefferson City
Joplin
Kansas City
Osage Beach
Rolla
Saint Joseph
Saint Louis
Sainte Genevieve
Springfield
Sullivan
Sunset Hills
Washington
Montana
Anaconda
Billings
Bozeman
Butte
Great Falls
Havre
Kalispell
Missoula
Nebraska
Grand Island
Kearney
Lincoln
Omaha
Papillion
New Hampshire
Exeter
New Mexico
Albuquerque
Rio Rancho
New York
Glens Falls
Lake Success
Mount Kisco
New York
Rochester
Sleepy Hollow
North Dakota
Bismarck
Fargo
Jamestown
Ohio
Centerville
Cincinnati
Dayton
Franklin
Greenville
Troy
Oklahoma
Oklahoma City
Oregon
Baker City
Bend
Clackamas
Coos Bay
Grants Pass
Hood River
Medford
Newberg
Ontario
Oregon City
Portland
Redmond
Pennsylvania
Allentown
Bethlehem
Danville
Dickson City
East Stroudsburg
Hazleton
Lewisburg
Scranton
Wilkes-Barre
Rhode Island
Westerly
South Carolina
Boiling Springs
Easley
Greenville
Greer
Seneca
South Dakota
Aberdeen
Mitchell
Pierre
Sioux Falls
Yankton
Texas
Conroe
Houston
League City
San Antonio
Sugar Land
Virginia
Martinsville
Richmond
South Hill
Tappahannock
Washington
Aberdeen
Bellingham
Centralia
Edmonds
Everett
Issaquah
Kennewick
Lacey
Longview
Mount Vernon
Seattle
Sedro-Woolley
Shelton
Silverdale
Spokane
Vancouver
Walla Walla
Yelm
West Virginia
Charleston
Wisconsin
Appleton
Ashland
Chippewa Falls
Eau Claire
Green Bay
Hayward
La Crosse
Ladysmith
Marshfield
Minocqua
Neillsville
New Richmond
Oconto Falls
Rice Lake
Sheboygan
Spooner
Stevens Point
Sturgeon Bay
Superior
Wausau
Weston
Wisconsin Rapids
Wyoming
Cody
Sheridan
PRIMARY OBJECTIVES:
I. To compare progression-free survival (PFS) in frail or selected intermediate fit newly diagnosed multiple myeloma (NDMM) participants treated with bortezomib with lenalidomide and dexamethasone (VRd-Lite) induction followed by lenalidomide maintenance (Arm 1) versus daratumumab and hyaluronidase-fihj (DRd) induction followed by lenalidomide maintenance (Arm 2).
II. To compare overall survival (OS) in frail or selected intermediate fit NDMM participants treated with VRd-Lite induction followed by lenalidomide maintenance (Arm 1) versus DRd induction followed by lenalidomide and daratumumab and hyaluronidase-fihj maintenance (Arm 3).
SECONDARY OBJECTIVES:
I. To compare PFS in Arm 1 versus Arm 3
II. To compare OS in Arm 1 versus Arm 2.
III. To compare OS in Arm 2 versus Arm 3, contingent upon significant results from both dual primary endpoints in favor of the respective experimental arms.
IV. To compare the overall response rate (ORR) of Arm 1 against the ORR of Arm 2 and Arm 3.
V. To assess the safety of Arm 1 with the safety of Arm 2 and Arm 3.
VI. To evaluate the rate of the composite endpoint of incidence of symptomatic venous thromboembolism (VTE), arterial thromboembolism (ATE), myocardial infarction (MI), cerebrovascular accident (CVA), and sudden death among participants receiving antithrombotic prophylaxis in conjunction with lenalidomide during the first nine months of study.
VII. To describe median time to response (complete response [CR] or better per International Myeloma Working Group [IMWG] criteria, very good partial response [VGPR] or better per IMWG criteria, partial response [PR] or better per IMWG criteria) on the three study arms.
PRIMARY QUALITY OF LIFE (QOL) OBJECTIVE:
I. To compare patient-reported global health status between treatment arms (Arm 1 versus the combination of Arms 2 and 3) at 9 months after randomization (end of induction therapy) using the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30).
SECONDARY QOL OBJECTIVE:
I. To compare longitudinal changes in global health status between treatment arms (Arm 1 versus the combination of Arms 2 and 3) from baseline to 9 months after randomization (end of induction therapy).
PATIENT REPORTED OUTCOMES-COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE) OBJECTIVE:
I. To compare selected patient-reported outcome symptoms using PRO-CTCAE items among the 3 study arms.
ADDITIONAL OBJECTIVES:
I. To compare the rate of minimal residual disease (MRD) by clonoSEQ (Registered Trademark) after 9 cycles of induction in Arm 1 versus Arm 2 and Arm 3, respectively.
II. To compare the rate of MRD conversion after 1 year of maintenance in participants who were MRD positive after induction in Arm 1 versus Arm 2 and Arm 3, respectively.
III. To compare the rate of sustained MRD negativity at time points of post-induction, post-1 year maintenance in Arm 1 versus Arm 2 and Arm 3, respectively.
BANKING OBJECTIVES:
I. To bank specimens for future correlative studies.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I (VRd-Lite):
INDUCTION CYCLES 1-9: Patients receive bortezomib subcutaneously (SC) on days 1, 8, 15, and 22 of each cycle, lenalidomide orally (PO) on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.
MAINTENANCE CYCLES 10+: Patients receive lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM II (DRd-R):
INDUCTION CYCLES 1-9: Patients receive daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.
MAINTENANCE CYCLES 10+: Patients receive lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM III (DRd-DR):
INDUCTION CYCLES 1-9: Patients receive daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.
MAINTENANCE CYCLES 10+: Patients receive daratumumab and hyaluronidase-fihj SC on day 1 of each cycle and lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
All patients undergo blood sample collection and bone marrow biopsy and aspiration throughout the trial. Patients also undergo positron emission tomography and computed tomography (PET)/(CT) throughout the trial as clinically indicated.
After completion of study treatment, patients are followed up every 3 months for 1 year, every 6 months for 2 years, and then annually (or more frequently at the provider’s discretion) for up to 10 years.
Trial PhasePhase III
Trial Typetreatment
Lead OrganizationSWOG
Principal InvestigatorSikander Ailawadhi
- Primary IDS2209
- Secondary IDsNCI-2022-05722
- ClinicalTrials.gov IDNCT05561387